Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

Bristol-Myers Squibb's Opdivo lassoes lung-cancer indication

The FDA granted the drug Priority Review status just last week.

HCB Health acquires Topin & Associates

HCB Health acquires Topin & Associates

Austin-based HCB Health announced Tuesday its acquisition of Chicago indie agency Topin & Associates in an effort to push the borders of its client base.

Orexigen pleases shareholders, irks FDA

The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.

Haymarket Media acquires digital agency Group DCA

Haymarket Media acquires digital agency Group DCA

Haymarket purchased HCP-engagement specialist Group DCA and will operate the digital agency out of its custom medical communications division.

Five things for pharma marketers to know: Wednesday, March 4

Five things for pharma marketers to know: Wednesday, March 4

FDA adds new language to low-T drug labels; Afrezza's launch has a poor start, investors say; BMS acquires prostate-cancer vaccine in a deal worth $975 million.

Researchers find safety disclaimers do not register with consumers

The study indicates patients discount wording that indicates the FDA has not approved supplement claims.

Safety advocate, DOJ settle kickback allegations

The agreement includes a $1-million payment.

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

IPG merges ICC Lowe shops into FCB Health, amid sluggish digital growth

Holding company will now focus on two health networks—FCB Health and McCann Health

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

Analysts say head-to-head study results could make Kyprolis the lead treatment.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters